Fortress Biotech, Inc.

  • Home
  • About
    • Overview
    • Business Development
    • Management Team
    • Board of Directors
    • FAQ
  • Programs
    • Pipeline
    • Marketed Products
    • Publications
  • News & Media
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News / Events
    • Company Info
    • Financial Info
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Resources
  • Contact
  • Careers
  • FAQ
  • Accessibility Statement

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events

Mustang Bio Reports First Quarter 2017 Financial Results and Recent Corporate Highlights

May 15, 2017

Fortress Biotech Reports First Quarter 2017 Financial Results and Recent Corporate Highlights

May 10, 2017

Fortress Biotech Announces Final Patient Dosed in Phase 1B Trial of CAEL-101 for the Treatment of AL Amyloidosis

May 04, 2017

Checkpoint Therapeutics to Present at PIONEERS 2017 Presented by Joseph Gunnar & Co.

Apr 27, 2017

Fortress Biotech to Present at PIONEERS 2017 Presented by Joseph Gunnar & Co.

Apr 27, 2017

Mustang Bio Announces Appointment of Manuel Litchman, M.D., as President and Chief Executive Officer

Apr 24, 2017

Fortress Biotech Announces Orphan Drug Designations for CAEL-101 in Amyloidosis

Apr 05, 2017

Checkpoint Therapeutics Reports Preclinical Data for Two Oncology Programs

Apr 04, 2017

Fortress Biotech to Present at BioCentury’s 24th Annual Future Leaders in the Biotech Industry Conference

Mar 30, 2017

Checkpoint Therapeutics to Present Preclinical Data at the American Association for Cancer Research Annual Meeting 2017

Mar 20, 2017
RSS
  • Prev
    • 1...
    • 48
    • 49
    • 50
    • 51
    • 52
    • 53
    • 54
    • 55
    • 56
    • 57
    Next

    Fortress Biotech programs include product candidates in development at Fortress, its majority-owned and majority-controlled partner companies and entities in which it holds minority ownership positions.

    © 2023 Fortress Biotech, Inc. All Rights Reserved.
    Facebook Twitter Linkedin
    Accessibility Statement Privacy Policy Disclaimer Sitemap